Protein kinase C mediates amyloid β-protein fragment 31–35-induced suppression of hippocampal late-phase long-term potentiation in vivo

Abstract

Amyloid β-protein (Aβ) in the brain of Alzheimer’s disease (AD) plays a detrimental role in synaptic plasticity and cognitive function. The effects of Aβ on the early-phase long-term potentiation (E-LTP) have been reported widely. However, whether the late-phase long-term potentiation (L-LTP), which differs from E-LTP mechanistically, is also affected by Aβ is still an open question. The present study examined the effects of intracerebraventricular injection of Aβ fragments 25–35 and 31–35 on the L-LTP in the CA1 area of rat hippocampus in vivo, and further investigated its possible underlying mechanism. Our results showed that: (1) Aβ25–35 (6.25–25 nmol) did not affect the baseline field excitatory postsynaptic potentials, but dose-dependently suppressed multiple high-frequency stimuli-induced L-LTP; (2) Aβ31–35, a shorter Aβ fragment than Aβ25–35, also significantly suppressed L-LTP, with the same suppressive effects as Aβ25–35; (3) pretreatment with PMA (6 nmol/5 μl), a membrane permeable PKC agonist, effectively prevented Aβ31–35-induced deficits in the early and the late components of L-LTP; (4) co-application of Aβ31–35 and chelerythrine (12 nmol/5 μl), a PKC antagonist, caused no additive suppression of L-LTP. These results indicate that both Aβ25–35 and Aβ31–35 can impair hippocampal synaptic plasticity in vivo by suppressing the maintenance of L-LTP, and PKC probably mediates the Aβ-induced suppression of hippocampal L-LTP. In addition, the similar efficacy of Aβ31–35 and Aβ25–35 in L-LTP suppression supports the hypothesis we suggested previously that the sequence 31–35 in Aβ might be the shortest active sequence responsible for the neuronal toxicity induced by full length of Aβ molecules.